pteridines has been researched along with Lupus Erythematosus, Systemic in 1 studies
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wirleitner, B | 1 |
| Obermoser, G | 1 |
| Böck, G | 1 |
| Neurauter, G | 1 |
| Schennach, H | 1 |
| Sepp, N | 1 |
| Fuchs, D | 1 |
1 other study available for pteridines and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Induction of apoptosis in human blood T cells by 7,8-dihydroneopterin: the difference between healthy controls and patients with systemic lupus erythematosus.
Topics: Adult; Annexin A5; Antioxidants; Apoptosis; Cells, Cultured; Concanavalin A; Cytokines; Dose-Respons | 2003 |